Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denise M Wolf

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Nature Communications|December 9, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumorsMark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Cell|August 12, 2014
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originKatherine A Hoadley, Christina Yau, Denise M Wolf, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2011
Subtype and pathway specific responses to anticancer compounds in breast cancerLaura M Heiser, Anguraj Sadanandam, Wen-Lin Kuo, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Nature Communications|December 9, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumorsMark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Cell|August 12, 2014
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originKatherine A Hoadley, Christina Yau, Denise M Wolf, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2011
Subtype and pathway specific responses to anticancer compounds in breast cancerLaura M Heiser, Anguraj Sadanandam, Wen-Lin Kuo, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
Pageof 7